AFP and hepatocellular carcinoma: A meta-analysis of 41 studies revealed a suboptimal performance for AFP in detecting early-stage HCC (overall sensitivity 49%, specificity 88%) (Singal et al. 2022), while the combinational use of US with AFP improved the sensitivity (74%) but decreased the specificity (83.9%).